SE9901387D0 - New pharmaceutical foromaulations - Google Patents

New pharmaceutical foromaulations

Info

Publication number
SE9901387D0
SE9901387D0 SE9901387A SE9901387A SE9901387D0 SE 9901387 D0 SE9901387 D0 SE 9901387D0 SE 9901387 A SE9901387 A SE 9901387A SE 9901387 A SE9901387 A SE 9901387A SE 9901387 D0 SE9901387 D0 SE 9901387D0
Authority
SE
Sweden
Prior art keywords
inhibitor compound
bile acid
ibat inhibitor
foromaulations
new pharmaceutical
Prior art date
Application number
SE9901387A
Other languages
English (en)
Swedish (sv)
Inventor
Bertil Abrahamsson
Ann-Margret Lindqvist
Anna-Lena Ungell
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9901387A priority Critical patent/SE9901387D0/xx
Publication of SE9901387D0 publication Critical patent/SE9901387D0/xx
Priority to JP2000611946A priority patent/JP2002542208A/ja
Priority to ES00928046T priority patent/ES2241603T3/es
Priority to NZ514264A priority patent/NZ514264A/en
Priority to EP00928046A priority patent/EP1173205B1/en
Priority to PT00928046T priority patent/PT1173205E/pt
Priority to PL00351186A priority patent/PL351186A1/xx
Priority to CN00806493A priority patent/CN1348384A/zh
Priority to DE60020551T priority patent/DE60020551T2/de
Priority to AU46335/00A priority patent/AU767425B2/en
Priority to CZ20013743A priority patent/CZ20013743A3/cs
Priority to KR1020017013297A priority patent/KR20010108516A/ko
Priority to TR2001/03033T priority patent/TR200103033T2/xx
Priority to PCT/SE2000/000755 priority patent/WO2000062810A1/en
Priority to AT00928046T priority patent/ATE296641T1/de
Priority to SK1528-2001A priority patent/SK15282001A3/sk
Priority to CA002379105A priority patent/CA2379105A1/en
Priority to IL14587100A priority patent/IL145871A0/xx
Priority to BR0009835-3A priority patent/BR0009835A/pt
Priority to HU0200793A priority patent/HUP0200793A3/hu
Priority to EEP200100545A priority patent/EE04607B1/xx
Priority to SI200030695T priority patent/SI1173205T1/xx
Priority to DK00928046T priority patent/DK1173205T3/da
Priority to IS6109A priority patent/IS2161B/is
Priority to ZA200108539A priority patent/ZA200108539B/en
Priority to NO20015063A priority patent/NO20015063D0/no
Priority to HK02104408A priority patent/HK1042850A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE9901387A 1999-04-19 1999-04-19 New pharmaceutical foromaulations SE9901387D0 (sv)

Priority Applications (27)

Application Number Priority Date Filing Date Title
SE9901387A SE9901387D0 (sv) 1999-04-19 1999-04-19 New pharmaceutical foromaulations
DK00928046T DK1173205T3 (da) 1999-04-19 2000-04-19 Oral formulering til ileum-indgivelse, omfattende en forbindelse til inhibering af ileum-galdesyretransporten
TR2001/03033T TR200103033T2 (tr) 1999-04-19 2000-04-19 íleuma uygulanmak zere ileum safra asidinin taçìnmasìnì inhibe eden bir bileçik i‡eren oral bir formlasyon
AT00928046T ATE296641T1 (de) 1999-04-19 2000-04-19 Orale formulierung zur verabreichung in den ileum enthaltend einen hemmstoff des ileum- gallensäuretransports
NZ514264A NZ514264A (en) 1999-04-19 2000-04-19 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
EP00928046A EP1173205B1 (en) 1999-04-19 2000-04-19 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
PT00928046T PT1173205E (pt) 1999-04-19 2000-04-19 Formulacao oral para administracao no ileo compreendendo um composto inibidor do transporte de acidos biliares no ileo
PL00351186A PL351186A1 (en) 1999-04-19 2000-04-19 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
CN00806493A CN1348384A (zh) 1999-04-19 2000-04-19 一种回肠给药的含有回肠胆汁酸转运抑制剂化合物的口服制剂
DE60020551T DE60020551T2 (de) 1999-04-19 2000-04-19 Orale formulierung zur verabreichung in den ileum enthaltend einen hemmstoff des ileum-gallensäuretransports
AU46335/00A AU767425B2 (en) 1999-04-19 2000-04-19 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
CZ20013743A CZ20013743A3 (cs) 1999-04-19 2000-04-19 Perorální farmaceutický přípravek pro aplikaci do ilea obsahující inhibitor transportu ľlučových kyselin
KR1020017013297A KR20010108516A (ko) 1999-04-19 2000-04-19 회장 담즙산 수송의 억제제 화합물을 포함하는 회장투여용 경구 제제
JP2000611946A JP2002542208A (ja) 1999-04-19 2000-04-19 回腸胆汁酸輸送阻害剤化合物を含む回腸投与のための経口製剤
PCT/SE2000/000755 WO2000062810A1 (en) 1999-04-19 2000-04-19 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
ES00928046T ES2241603T3 (es) 1999-04-19 2000-04-19 Formulacion oral para la administracion al ileon que comprende un compuesto inhibidor del transporte de acidos biliares presentes en el ileon.
SK1528-2001A SK15282001A3 (sk) 1999-04-19 2000-04-19 Perorálny farmaceutický prípravok na aplikáciu do ilea, obsahujúci inhibítor transportu žlčových kyselín
CA002379105A CA2379105A1 (en) 1999-04-19 2000-04-19 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
IL14587100A IL145871A0 (en) 1999-04-19 2000-04-19 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
BR0009835-3A BR0009835A (pt) 1999-04-19 2000-04-19 Formulação farmacêutica, uso da mesma, métodos para tratamento profilático ou terapêutico de um indivìduo que sofre, ou susceptìvel à hipercolesterolemia, e a diarréia, e, uso de um aglutinante de ácido da bile
HU0200793A HUP0200793A3 (en) 1999-04-19 2000-04-19 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
EEP200100545A EE04607B1 (et) 1999-04-19 2000-04-19 Niudesooles toimiv suukaudne ravimvorm, mis sisaldab niudesooles sapphapete transporti mõjutavat inhibiitorit
SI200030695T SI1173205T1 (en) 1999-04-19 2000-04-19 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
IS6109A IS2161B (is) 1999-04-19 2001-10-16 Samsetning fyrir dausgörn til inntöku um munn seminniheldur lata efnasamband fyrir dausgarnar gallsýru flutning
ZA200108539A ZA200108539B (en) 1999-04-19 2001-10-17 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport.
NO20015063A NO20015063D0 (no) 1999-04-19 2001-10-18 En oral formulering for administrering til ileum omfattende en inhibitorforbindelse til ileal-gallesyre transporten
HK02104408A HK1042850A1 (en) 1999-04-19 2002-06-12 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9901387A SE9901387D0 (sv) 1999-04-19 1999-04-19 New pharmaceutical foromaulations

Publications (1)

Publication Number Publication Date
SE9901387D0 true SE9901387D0 (sv) 1999-04-19

Family

ID=20415263

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9901387A SE9901387D0 (sv) 1999-04-19 1999-04-19 New pharmaceutical foromaulations

Country Status (27)

Country Link
EP (1) EP1173205B1 (pt)
JP (1) JP2002542208A (pt)
KR (1) KR20010108516A (pt)
CN (1) CN1348384A (pt)
AT (1) ATE296641T1 (pt)
AU (1) AU767425B2 (pt)
BR (1) BR0009835A (pt)
CA (1) CA2379105A1 (pt)
CZ (1) CZ20013743A3 (pt)
DE (1) DE60020551T2 (pt)
DK (1) DK1173205T3 (pt)
EE (1) EE04607B1 (pt)
ES (1) ES2241603T3 (pt)
HK (1) HK1042850A1 (pt)
HU (1) HUP0200793A3 (pt)
IL (1) IL145871A0 (pt)
IS (1) IS2161B (pt)
NO (1) NO20015063D0 (pt)
NZ (1) NZ514264A (pt)
PL (1) PL351186A1 (pt)
PT (1) PT1173205E (pt)
SE (1) SE9901387D0 (pt)
SI (1) SI1173205T1 (pt)
SK (1) SK15282001A3 (pt)
TR (1) TR200103033T2 (pt)
WO (1) WO2000062810A1 (pt)
ZA (1) ZA200108539B (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
IL151150A0 (en) * 2001-01-31 2003-04-10 Roehm Gmbh Multiparticulate drug form comprising at least two differently coated pellet forms
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
TWI331143B (en) 2001-09-08 2010-10-01 Astrazeneca Uk Ltd Benzothiadiazepine derivatives, process for preparing them, and pharmaceutical composition comprising them
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0216321D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
BRPI0912683A2 (pt) 2008-05-15 2016-01-26 Transmolecular Inc tratamento de tumores metastáticos
CN102316872B (zh) * 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
US8318663B2 (en) 2008-11-26 2012-11-27 Satiogen Pharmaceuticals, Inc. Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent
GB0900350D0 (en) * 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
CN102844044B (zh) 2010-02-04 2016-10-26 摩尔弗泰克有限公司 氯毒素多肽和结合物及其应用
EP2569330B1 (en) 2010-05-11 2016-09-28 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
AU2011326871B2 (en) 2010-11-08 2015-02-12 Albireo Ab IBAT inhibitors for the treatment of liver diseases
PT2637646T (pt) 2010-11-08 2016-08-17 Albireo Ab Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar
SG11201401816SA (en) * 2011-10-28 2014-05-29 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
EA201891154A1 (ru) * 2011-10-28 2019-02-28 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
AU2013359429A1 (en) 2012-12-10 2015-07-09 Fred Hutchinson Cancer Research Center Methods for screening
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
JP6751020B2 (ja) 2014-06-25 2020-09-02 Ｅａファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CN105362244A (zh) * 2015-11-26 2016-03-02 青岛海之源智能技术有限公司 考来烯胺缓释片及制备方法
CN108601745B (zh) 2016-02-09 2021-12-07 阿尔比里奥公司 口服考来烯胺制剂及其用途
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
WO2017138877A1 (en) 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CA3021011A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
CA3071182A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES2942443T3 (es) 2018-06-05 2023-06-01 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
TWI823954B (zh) 2018-06-20 2023-12-01 瑞典商艾爾比瑞歐公司 奧德維希百(odevixibat)之結晶修飾物
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
CA3127408A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP7504109B2 (ja) 2019-02-06 2024-06-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
BR112021015809A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Resposta dependente de genótipo e dose a um asbti em pacientes com deficiência de bomba de exportação de sal biliar
MX2022006731A (es) 2019-12-04 2022-06-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar.
AR120682A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
JP2023504643A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
TW202134222A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
JP2023504644A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP2023504647A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
PT4069360T (pt) 2019-12-04 2024-03-06 Albireo Ab Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN116157389A (zh) 2020-08-03 2023-05-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
CA3198216A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
AU2023255249A1 (en) 2022-04-22 2024-10-17 Albireo Ab Subcutaneous administration of an asbt inhibitor
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
US20240067617A1 (en) 2022-07-05 2024-02-29 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US20240207286A1 (en) 2022-12-09 2024-06-27 Albireo Ab Asbt inhibitors in the treatment of renal diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA941003B (en) * 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
TW289020B (pt) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤

Also Published As

Publication number Publication date
JP2002542208A (ja) 2002-12-10
DE60020551D1 (de) 2005-07-07
HUP0200793A3 (en) 2004-07-28
TR200103033T2 (tr) 2002-03-21
IS6109A (is) 2001-10-16
EP1173205A1 (en) 2002-01-23
SK15282001A3 (sk) 2002-04-04
WO2000062810A1 (en) 2000-10-26
IS2161B (is) 2006-11-15
ZA200108539B (en) 2003-01-17
EE200100545A (et) 2003-02-17
NZ514264A (en) 2003-10-31
IL145871A0 (en) 2002-07-25
NO20015063L (no) 2001-10-18
KR20010108516A (ko) 2001-12-07
AU767425B2 (en) 2003-11-13
ATE296641T1 (de) 2005-06-15
EP1173205B1 (en) 2005-06-01
HUP0200793A2 (hu) 2002-07-29
CZ20013743A3 (cs) 2002-01-16
PT1173205E (pt) 2005-10-31
DE60020551T2 (de) 2006-03-23
ES2241603T3 (es) 2005-11-01
CN1348384A (zh) 2002-05-08
NO20015063D0 (no) 2001-10-18
SI1173205T1 (en) 2005-10-31
HK1042850A1 (en) 2002-08-30
PL351186A1 (en) 2003-03-24
AU4633500A (en) 2000-11-02
DK1173205T3 (da) 2005-08-08
BR0009835A (pt) 2002-01-08
EE04607B1 (et) 2006-04-17
CA2379105A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
SE9901387D0 (sv) New pharmaceutical foromaulations
SE0003766D0 (sv) Novel formulation
BG105568A (en) Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent
IL124459A0 (en) Antagonists of gonadotropin releasing hormone
MX9804850A (es) Antagonistas de hormona liberadora de gonadotropina.
NZ325060A (en) Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone
BG105109A (en) Cell adhesion-inhibiting anti-inflammatory compounds
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
BG106057A (en) Method of enhancing the efficacy of anti-tumour agents
NZ515757A (en) Amorphous compounds and their pharmaceutical compositions
TW349865B (en) Therapeutic agent for hemorrhoidal diseases
TR200101337T2 (tr) Değiştirilmiş salımlı ensülin sensitizörü için farmasötik terkip ve kullanımı.
PT1165065E (pt) Comprimidos para degluticao com elevada concentracao de n-acetilcisteina
GB9907571D0 (en) Compounds
BG108144A (en) New use
EP1347754A4 (en) COMPOSITIONS FOR PREVENTION OF ADHESION
BG104692A (en) Extended release tiagabine formulation
AU2003241629A1 (en) An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
TR200102262T2 (tr) Koroner müdahale ile ilgili kardiovasküler olayların önlenmesi veya azaltılması için yöntem.
AU2001292423A1 (en) Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid
AU1580395A (en) Microgranules of 5-nitro imidazole derivatives
MY132962A (en) Inotropic agents with negative chronotropic and vasodilatory effects
TR200102245T2 (tr) Koroner müdahale ile ilgili kardiovasküler olayların önlenmesi veya azaltılması için yöntem.
ES2151383A1 (es) Derivado de hidroquinona, sus sales de hidrocloruro agente antialergico que lo comprende y farmaco antialergico correspondiente.
MX9603999A (es) Tratamiento de nefropatia diabetica con valsartan.